- Patients with a self-administered nasal spray application found to have reduced SARS-CoV-2 log viral load by more than 95% in infected participants within 24 hours of treatment, and by more than 99% in 72 hours
- Trial concluded that treatment accelerated clearance of SARS-CoV-2 by a factor of 16-fold versus a placebo
- Randomized, double-blind, placebo-controlled trial evaluated 79 confirmed cases of COVID-19, the majority heavily-infected with the UK variant
- No adverse events were recorded in the group
- Submission for Emergency Use in the UK and Canada for the treatment and prevention of COVID-19 is planned immediately
Read here (Business Wire, Mar 15, 2021)
